Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Frontiers in Pharmacology|October 5, 2020
Getting the Right Evidence After Drug ApprovalRick A Vreman, Hubert G M Leufkens, Aaron S Kesselheim
Clinical Pharmacology and Therapeutics|March 20, 2024
Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA OrganizationsJorge Madrid Paredes, Jan-Willem Versteeg, Rick A Vreman, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|September 5, 2022
Regulatory reliance pathways during health emergencies: enabling timely authorizations for COVID-19 vaccines in Latin AmericaIvar T van der Zee, Rick A Vreman, Lawrence Liberti, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2022
Reported Challenges in Health Technology Assessment of Complex Health TechnologiesMilou A Hogervorst, Rick A Vreman, Aukje K Mantel-Teeuwisse, et al.
International Journal of Environmental Research and Public Health|January 8, 2023
When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital DrugsMarcelien H E Callenbach, Rick A Vreman, Aukje K Mantel-Teeuwisse, et al.
Frontiers in Pharmacology|February 28, 2022
Real World Data in Health Technology Assessment of Complex Health TechnologiesMilou A Hogervorst, Johan Pontén, Rick A Vreman, et al.
International Journal of Technology Assessment in Health Care|January 31, 2022
Understanding innovation of health technology assessment methods: the IHTAM frameworkLi Jiu, Milou A Hogervorst, Rick A Vreman, et al.
International Journal of Environmental Research and Public Health|November 13, 2020
Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility AnalysisRick A Vreman, Thomas F Broekhoff, Hubert Gm Leufkens, et al.
Drug Discovery Today|November 13, 2022
Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlookMarcelien H E Callenbach, Lldikó Ádám, Rick A Vreman, et al.
Pharmacoeconomics|October 5, 2024
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their SuitabilityMarcelien H E Callenbach, Rick A Vreman, Christine Leopold, et al.
Pageof 5